Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ankush Sachdeva

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Cancers|July 2, 2021
Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II TrialMinsong Cao, Yu Gao, Stephanie M Yoon, et al.
Cell Reports. Medicine|November 13, 2024
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancersYiqian Gu, Ann Ly, Sara Rodriguez, et al.
European Urology|March 17, 2024
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical TrialJohn Nikitas, Matthew Rettig, John Shen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trialJohn Nikitas, Lauren M Smith, Yu Gao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 14, 2020
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell CarcinomaIzak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2022
Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 TrialTing Martin Ma, Leslie K Ballas, Holly Wilhalme, et al.
JAMA Oncology|May 15, 2025
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical TrialJohn Nikitas, Leslie K Ballas, Tahmineh Romero, et al.
International Journal of Radiation Oncology, Biology, Physics|June 21, 2020
Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate CancerNeil R Parikh, Amar U Kishan, Nathanael Kane, et al.
European Urology|October 1, 2025
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical TrialAmar U Kishan, Jesus E Juarez Casillas, Paul Sargos, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancers|July 2, 2021
Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II TrialMinsong Cao, Yu Gao, Stephanie M Yoon, et al.
Cell Reports. Medicine|November 13, 2024
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancersYiqian Gu, Ann Ly, Sara Rodriguez, et al.
European Urology|March 17, 2024
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical TrialJohn Nikitas, Matthew Rettig, John Shen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trialJohn Nikitas, Lauren M Smith, Yu Gao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 14, 2020
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell CarcinomaIzak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2022
Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 TrialTing Martin Ma, Leslie K Ballas, Holly Wilhalme, et al.
JAMA Oncology|May 15, 2025
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical TrialJohn Nikitas, Leslie K Ballas, Tahmineh Romero, et al.
International Journal of Radiation Oncology, Biology, Physics|June 21, 2020
Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate CancerNeil R Parikh, Amar U Kishan, Nathanael Kane, et al.
European Urology|October 1, 2025
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical TrialAmar U Kishan, Jesus E Juarez Casillas, Paul Sargos, et al.
Pageof 3